<p>新世界顾问公司在最近向美国证券交易委员会（SEC）披露的信息中表示，在第二季度将其在强生（NYSE:JNJ - 免费报告）股票中的持仓增加了 61.4%。该基金在季度内购买了 1,347 股后，持有该公司 3,541 股股票。截至其最近向 SEC 提交的文件，新世界顾问公司在强生的持股价值为 541,000 美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>为什么 GRAIL 股票可能是生物科技的下一个重大突破</li>
</ul>
<p>其他几家机构投资者和对冲基金也对该公司的持仓进行了调整。先锋集团在第二季度将其在强生的股份增加了 1.3%。先锋集团目前拥有 237,047,859 股该公司的股票，价值 36,209,060,000 美元，在上个季度又购买了 3,085,180 股。Geode Capital Management LLC 在第二季度将其在强生的持股增加了 2.1%。Geode Capital Management LLC 目前拥有 60,609,476 股该公司的股票，价值 9,227,988,000 美元，在此期间又收购了 1,225,676 股。北方信托公司在第一季度将其在强生的持仓提高了 0.4%。北方信托公司目前拥有 30,943,820 股该公司的股票，价值 5,131,723,000 美元，在上个季度又购买了 130,645 股。纽约梅隆银行在第二季度将其在强生的股份增加了 2.7%。纽约梅隆银行目前拥有 23,802,503 股该公司的股票，价值 3,635,832,000 美元，在此期间又购买了 620,039 股。最后，法律与一般集团在第二季度将其在强生的持仓增加了 6.2%。法律与一般集团目前拥有 18,917,274 股该公司的股票，价值 2,889,614,000 美元，在上个季度又购买了 1,097,855 股。69.55% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>强生股票表现</h2>
<p>强生（NYSE:JNJ）周五开盘价为 203.88 美元。该公司的 50 日简单移动平均线为 188.25 美元，200 日简单移动平均线为 171.55 美元。公司流动比率为 0.80，当前比率为 1.07，债务与股本比率为 0.50。该股票的市值为 4912.1 亿美元，市盈率为 19.68，市盈率增长比率为 2.19，贝塔值为 0.38。强生的 52 周低点为 140.68 美元，52 周高点为 206.94 美元。</p>
<ul>
<li>3 只适合不安市场的防御性股票</li>
</ul>
<p>强生（NYSE:JNJ - 获取免费报告）最近于 8 月 30 日发布了季度财报。公司报告本季度每股收益为 2.26 美元。该公司本季度的收入为 240.2 亿美元。强生的净利润率为 27.26%，股本回报率为 32.73%。分析师预计强生在当前财政年度的每股收益将达到 10.58 美元。</p>
<h2>强生宣布分红</h2>
<p>该公司还最近披露了一项季度分红，将于 12 月 9 日支付。11 月 25 日的登记投资者将获得 1.30 美元的分红。这相当于年化 5.20 美元的分红，收益率为 2.6%。该分红的除息日为 11 月 25 日。强生的分红支付比率目前为 50.19%。</p>
<h2>内部人士下注</h2>
<ul>
<li>持有评级，高回报？3 只可能超出预期的股票</li>
</ul>
<p>在其他强生新闻中，执行副总裁 Jennifer L. Taubert 于 9 月 4 日星期四出售了 56,471 股强生股票。股票以 177.81 美元的平均价格出售，总交易额为 10,041,108.51 美元。交易完成后，该执行副总裁在公司持有 178,013 股，价值约 31,652,491.53 美元。此次交易使其持股减少了 24.08%。该交易已在 SEC 的法律文件中披露，可以通过此链接访问。公司内部人士持有该公司 0.16% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票研究分析师最近对该股票发表了评论。花旗集团将强生股票的目标价格从 213.00 美元上调至 215.00 美元，并在 10 月 15 日的报告中给予公司 “买入” 评级。高盛集团将强生的目标价格从 186.00 美元上调至 212.00 美元，并在 10 月 9 日的研究报告中给予公司 “买入” 评级。加拿大丰业银行在 11 月 13 日的研究报告中开始覆盖强生，给予 “行业表现优于大盘” 评级，并设定 230.00 美元的目标价格。大和资本市场在 10 月 20 日的研究报告中将强生的评级从 “中性” 上调至 “表现优于大盘”，并设定 203.00 美元的目标价格。最后，富国银行在 10 月 3 日的报告中设定强生的目标价格为 212.00 美元，并给予该股票 “超配” 评级。四位投资分析师给予该股票 “强烈买入” 评级，十三位给予 “买入” 评级，九位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 201.05 美元。</p>
<p><strong>查看我们关于 JNJ 的最新报告</strong></p>
<h2>强生简介</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，胜过强生</li>
<li>什么样的股票是好的分红股票？</li>
<li>MarketBeat 周报 – 11/17 - 11/21</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>一项宏伟的人工智能投资？斯坦利·德鲁肯米勒的最新科技动态</li>
<li>股票交易术语 - 每位投资者都需要了解的股票术语</li>
<li>12 位分析师刚刚上调了 CrowdStrike 的目标价——他们预见了什么</li>
</ul>
<p><strong>想看看其他对强生持有股份的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取强生（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>新世界顾问公司（New World Advisors LLC）在第二季度将其在强生（Johnson & Johnson）的持股增加了 61.4%，目前持有 3,541 股，价值 54.1 万美元。其他机构投资者如先锋集团（Vanguard）、Geode Capital 和法律与一般保险公司（Legal & General）也调整了他们的持仓。强生的股票开盘价为 203.88 美元，市值为 4912.1 亿美元。该公司宣布季度股息为 1.30 美元，将于 12 月 9 日支付</p>

<p>New World Advisors LLC grew its position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 61.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,541 shares of the company's stock after purchasing an additional 1,347 shares during the quarter. New World Advisors LLC's holdings in Johnson &amp; Johnson were worth $541,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>新世界顾问公司在最近向美国证券交易委员会（SEC）披露的信息中表示，在第二季度将其在强生（NYSE:JNJ - 免费报告）股票中的持仓增加了 61.4%。该基金在季度内购买了 1,347 股后，持有该公司 3,541 股股票。截至其最近向 SEC 提交的文件，新世界顾问公司在强生的持股价值为 541,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能是生物科技的下一个重大突破</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Johnson &amp; Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company's stock valued at $36,209,060,000 after buying an additional 3,085,180 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Johnson &amp; Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company's stock valued at $9,227,988,000 after acquiring an additional 1,225,676 shares during the period. Northern Trust Corp raised its position in Johnson &amp; Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock valued at $5,131,723,000 after purchasing an additional 130,645 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Johnson &amp; Johnson by 2.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company's stock worth $3,635,832,000 after purchasing an additional 620,039 shares during the period. Finally, Legal &amp; General Group Plc grew its position in Johnson &amp; Johnson by 6.2% during the 2nd quarter. Legal &amp; General Group Plc now owns 18,917,274 shares of the company's stock worth $2,889,614,000 after purchasing an additional 1,097,855 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金也对该公司的持仓进行了调整。先锋集团在第二季度将其在强生的股份增加了 1.3%。先锋集团目前拥有 237,047,859 股该公司的股票，价值 36,209,060,000 美元，在上个季度又购买了 3,085,180 股。Geode Capital Management LLC 在第二季度将其在强生的持股增加了 2.1%。Geode Capital Management LLC 目前拥有 60,609,476 股该公司的股票，价值 9,227,988,000 美元，在此期间又收购了 1,225,676 股。北方信托公司在第一季度将其在强生的持仓提高了 0.4%。北方信托公司目前拥有 30,943,820 股该公司的股票，价值 5,131,723,000 美元，在上个季度又购买了 130,645 股。纽约梅隆银行在第二季度将其在强生的股份增加了 2.7%。纽约梅隆银行目前拥有 23,802,503 股该公司的股票，价值 3,635,832,000 美元，在此期间又购买了 620,039 股。最后，法律与一般集团在第二季度将其在强生的持仓增加了 6.2%。法律与一般集团目前拥有 18,917,274 股该公司的股票，价值 2,889,614,000 美元，在上个季度又购买了 1,097,855 股。69.55% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>强生股票表现</h2>
</div><p>NYSE:JNJ opened at $203.88 on Friday. The firm's fifty day simple moving average is $188.25 and its 200-day simple moving average is $171.55. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $491.21 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson &amp; Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $206.94.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ）周五开盘价为 203.88 美元。该公司的 50 日简单移动平均线为 188.25 美元，200 日简单移动平均线为 171.55 美元。公司流动比率为 0.80，当前比率为 1.07，债务与股本比率为 0.50。该股票的市值为 4912.1 亿美元，市盈率为 19.68，市盈率增长比率为 2.19，贝塔值为 0.38。强生的 52 周低点为 140.68 美元，52 周高点为 206.94 美元。</p>
</div><ul>
<li>3 Smart Defensive Stocks for an Uneasy Market</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只适合不安市场的防御性股票</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts expect that Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近于 8 月 30 日发布了季度财报。公司报告本季度每股收益为 2.26 美元。该公司本季度的收入为 240.2 亿美元。强生的净利润率为 27.26%，股本回报率为 32.73%。分析师预计强生在当前财政年度的每股收益将达到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>强生宣布分红</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson &amp; Johnson's dividend payout ratio is presently 50.19%.</p>
<div class="lb-trans"><p>该公司还最近披露了一项季度分红，将于 12 月 9 日支付。11 月 25 日的登记投资者将获得 1.30 美元的分红。这相当于年化 5.20 美元的分红，收益率为 2.6%。该分红的除息日为 11 月 25 日。强生的分红支付比率目前为 50.19%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations</li>
</ul>
<div class="lb-trans"><ul>
<li>持有评级，高回报？3 只可能超出预期的股票</li>
</ul>
</div><p>In other Johnson &amp; Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson &amp; Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他强生新闻中，执行副总裁 Jennifer L. Taubert 于 9 月 4 日星期四出售了 56,471 股强生股票。股票以 177.81 美元的平均价格出售，总交易额为 10,041,108.51 美元。交易完成后，该执行副总裁在公司持有 178,013 股，价值约 31,652,491.53 美元。此次交易使其持股减少了 24.08%。该交易已在 SEC 的法律文件中披露，可以通过此链接访问。公司内部人士持有该公司 0.16% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities research analysts have recently commented on the stock. Citigroup upped their target price on shares of Johnson &amp; Johnson from $213.00 to $215.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, October 15th. The Goldman Sachs Group upped their price objective on Johnson &amp; Johnson from $186.00 to $212.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, October 9th. Scotiabank started coverage on Johnson &amp; Johnson in a research note on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $230.00 target price on the stock. Daiwa Capital Markets upgraded Johnson &amp; Johnson from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $203.00 price target for the company in a research note on Monday, October 20th. Finally, Wells Fargo &amp; Company set a $212.00 price target on Johnson &amp; Johnson and gave the stock an &#34;overweight&#34; rating in a report on Friday, October 3rd. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $201.05.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对该股票发表了评论。花旗集团将强生股票的目标价格从 213.00 美元上调至 215.00 美元，并在 10 月 15 日的报告中给予公司 “买入” 评级。高盛集团将强生的目标价格从 186.00 美元上调至 212.00 美元，并在 10 月 9 日的研究报告中给予公司 “买入” 评级。加拿大丰业银行在 11 月 13 日的研究报告中开始覆盖强生，给予 “行业表现优于大盘” 评级，并设定 230.00 美元的目标价格。大和资本市场在 10 月 20 日的研究报告中将强生的评级从 “中性” 上调至 “表现优于大盘”，并设定 203.00 美元的目标价格。最后，富国银行在 10 月 3 日的报告中设定强生的目标价格为 212.00 美元，并给予该股票 “超配” 评级。四位投资分析师给予该股票 “强烈买入” 评级，十三位给予 “买入” 评级，九位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 201.05 美元。</p>
</div><p><strong>Check Out Our Latest Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 JNJ 的最新报告</strong></p>
</div><h2>Johnson &amp; Johnson Profile</h2>
<div class="lb-trans"><h2>强生简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>MarketBeat Week in Review – 11/17 - 11/21</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过强生</li>
<li>什么样的股票是好的分红股票？</li>
<li>MarketBeat 周报 – 11/17 - 11/21</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>一项宏伟的人工智能投资？斯坦利·德鲁肯米勒的最新科技动态</li>
<li>股票交易术语 - 每位投资者都需要了解的股票术语</li>
<li>12 位分析师刚刚上调了 CrowdStrike 的目标价——他们预见了什么</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对强生持有股份的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取强生（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

New World Advisors LLC 增加了其在强生公司 $JNJ 的股票持仓